2010
DOI: 10.1111/j.1600-0625.2010.01151.x
|View full text |Cite
|
Sign up to set email alerts
|

Diagnostic value and prognostic significance of plasmatic proteasome level in patients with melanoma

Abstract: Plasmatic proteasome (p-proteasome) also called circulating proteasome has recently been described as a tumor marker. We investigated the diagnostic and prognostic accuracies of p-proteasome levels in a melanoma population classified according to the American Joint Committee on Cancer staging system. Using an ELISA test, we measured p-proteasome levels in 90 patients and 40 controls between March 2003 and March 2008. The subunit composition of p-proteasomes was determined in metastatic melanoma by proteomic an… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
2
1

Citation Types

0
20
0

Year Published

2011
2011
2019
2019

Publication Types

Select...
8

Relationship

1
7

Authors

Journals

citations
Cited by 18 publications
(20 citation statements)
references
References 42 publications
0
20
0
Order By: Relevance
“…Significantly elevated plasma proteasome concentrations were reported in a group of 20 patients with different epithelial solid tumors (breast, renal, gastric, kidney, colon, testicle, or lung) [25] and more recently in a large cohort of 120 patients with newly diagnosed epithelial ovarian cancer employing ELISA-based assay [29]. In addition, data from a study conducted in patients with malignant melanoma demonstrated significantly elevated circulating proteasome concentration in stages III/IV vs. stages I/II [27,28]. It is worth of note that in stage I/II malignant melanoma patients, plasma proteasome concentration was not significantly different from that observed in normal volunteers [27].…”
Section: Discussionmentioning
confidence: 93%
See 1 more Smart Citation
“…Significantly elevated plasma proteasome concentrations were reported in a group of 20 patients with different epithelial solid tumors (breast, renal, gastric, kidney, colon, testicle, or lung) [25] and more recently in a large cohort of 120 patients with newly diagnosed epithelial ovarian cancer employing ELISA-based assay [29]. In addition, data from a study conducted in patients with malignant melanoma demonstrated significantly elevated circulating proteasome concentration in stages III/IV vs. stages I/II [27,28]. It is worth of note that in stage I/II malignant melanoma patients, plasma proteasome concentration was not significantly different from that observed in normal volunteers [27].…”
Section: Discussionmentioning
confidence: 93%
“…So far, circulating proteasome has been detected in patients with solid tumors using the ELISA test employing antibodies directed against the constitutive α subunits of the 20S proteasome [25][26][27][28][29][30]. However, ELISA-based assay Fig.…”
Section: Discussionmentioning
confidence: 99%
“…Besides morphological and histopathological markers, several molecular markers have diagnostic and prognostic utility (1). These include markers on the melanoma, for example methylthioadenosine phosphorylase (MTAP) (2), nestin and SOX9 (3), and markers in patients' blood, for example p-proteasome levels (4). The search for a prognostic marker continues, however.…”
Section: Introductionmentioning
confidence: 99%
“…Data are presented as means ± SD. *P < 0.05; **P < 0.001. novel strategies for several diseases including cancer progression and cystic fibrosis (8,(20)(21)(22)(23)(24). Here, we provide evidence for the first time that the inhibition of the UPS increases the stabilization of cell-cell contacts in human keratinocytes, which might be mediated by the maintenance of DP at desmosomes.…”
Section: Resultsmentioning
confidence: 99%